Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Propanc Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PPCB
Over the counter
8731
https://www.propanc.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Propanc Biopharma Inc
Propanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office
- Apr 16th, 2024 1:00 pm
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
- Apr 8th, 2024 1:00 pm
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study
- Feb 22nd, 2024 1:00 pm
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
- Jan 16th, 2024 2:00 pm
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
- Dec 18th, 2023 2:00 pm
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
- Dec 13th, 2023 2:00 pm
James Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDaily
- Dec 12th, 2023 12:00 pm
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
- Nov 7th, 2023 2:00 pm
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
- Aug 15th, 2023 12:30 pm
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
- Jul 25th, 2023 1:00 pm
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
- Jul 13th, 2023 12:30 pm
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
- Jul 5th, 2023 1:00 pm
Propanc Biopharma Provides Shareholder Update
- Jun 22nd, 2023 1:00 pm
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
- May 25th, 2023 1:00 pm
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
- May 23rd, 2023 12:30 pm
Propanc Biopharma Announces Reverse Stock Split
- May 23rd, 2023 2:44 am
Scroll